Form 4: Sensei Biotherapeutics Insider Stock Sale

Reporting person James Peyer sold 25,000 shares of Sensei Biotherapeutics common stock on June 1, 2026.

Summary

• James Peyer, a 10% owner of Sensei Biotherapeutics, Inc. (SNSE), executed the sale of 25,000 shares of common stock.
• The transaction occurred on June 1, 2026, in two separate tranches.
• The first tranche of 24,524 shares was sold at a weighted average price of $20.00.
• The second tranche of 476 shares was sold at a price of $21.14.
• Following these transactions, the reporting person retains beneficial ownership of 130,142 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine disclosure of insider stock divestment without accompanying negative operational news.

Positives

• The sale was executed at price points between $20.00 and $21.14, reflecting current market valuation levels.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term price appreciation.

Risks

• Continued divestment by major shareholders may exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions in the biotechnology sector are common for liquidity purposes and do not always signal a change in fundamental company outlook.

Comparison to Industry Standards

• Insider sales by 10% owners are standard regulatory filings and align with typical liquidity events for major stakeholders in mid-cap biotech firms.

Stakeholder Impact

• Shareholders should monitor for further insider activity to gauge long-term sentiment from major stakeholders.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Sensei Biotherapeutics, SNSE, Insider Trading, Form 4, Biotech, Stock Sale